These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 37718634)

  • 1. Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China.
    Pu X; Xu C; Wang Q; Wang W; Wu F; Cai X; Song Z; Yu J; Zhong W; Wang Z; Zhang Y; Liu J; Zhang S; Liu A; Li W; Zhan P; Liu H; Lv T; Miao L; Min L; Lin G; Huang L; Yuan J; Jiang Z; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Zhang J; Guo H; Chu Q; Meng R; Liu X; Wu J; Zhou J; Zhu Z; Pan W; Pang F; Huang J; Wang K; Wu F; Shen T; Zou S; Xu B; Wang L; Zhu Y; Lin X; Cai J; Xu L; Li J; Jiao X; Li K; Feng H; Wang L; Du Y; Yao W; Shi X; Niu X; Yuan D; Yao Y; Kang J; Zhang J; Zhang C; Fu J; Huang J; Zhang Y; Sun P; Wang H; Ye M; Wang D; Wang Z; Hao Y; Wang Z; Wan B; Lv D; Lan G; Yang S; Shi L; Wang Y; Li B; Zhang Z; Li Z; Li Y; Liu Z; Yang N; Wang H; Huang W; Hong Z; Wang G; Wang J; Fang M; Fang Y; Zhu X; Shen Y; Zhang Y; Ma S; Song Y; Lu Y; Fang W; Li Z; Wu L
    Thorac Cancer; 2023 Nov; 14(31):3166-3177. PubMed ID: 37718634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
    Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
    Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chinese expert consensus on the diagnosis and treatment of advanced RET fusion-positive non-small cell lung cancer (2023 edition)].
    ; ;
    Zhonghua Zhong Liu Za Zhi; 2023 Dec; 45(12):991-1002. PubMed ID: 38110308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
    Sun F; McCoach CE
    Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
    Ferrara R; Auger N; Auclin E; Besse B
    J Thorac Oncol; 2018 Jan; 13(1):27-45. PubMed ID: 29128428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.
    Belluomini L; Avancini A; Pasqualin L; Insolda J; Sposito M; Menis J; Tregnago D; Trestini I; Ferrara MG; Bria E; Milella M; Pilotto S
    Expert Rev Anticancer Ther; 2022 Aug; 22(8):785-794. PubMed ID: 35726802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.
    Russo GL; Bironzo P; Bennati C; Bonanno L; Catino A; Metro G; Petrini I; Russano M; Passaro A
    Crit Rev Oncol Hematol; 2024 Feb; 194():104243. PubMed ID: 38135019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Syed YY
    Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
    Novello S; Califano R; Reinmuth N; Tamma A; Puri T
    Oncologist; 2023 May; 28(5):402-413. PubMed ID: 36821595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China.
    Li T; Yang WY; Liu TT; Li Y; Liu L; Zheng X; Zhao L; Zhang F; Hu Y
    Technol Cancer Res Treat; 2023; 22():15330338221148802. PubMed ID: 36628459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting RET alterations in non-small cell lung cancer.
    Nishikawa G; Klein MA
    Curr Probl Cancer; 2024 Apr; 49():101074. PubMed ID: 38494387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].
    Gao Q; Su J; Xiao F; Lin X; Yang J
    Zhongguo Fei Ai Za Zhi; 2021 Dec; 24(12):853-861. PubMed ID: 34743497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
    Servetto A; Esposito D; Ferrara R; Signorelli D; Belli S; Napolitano F; Santaniello A; Ciciola P; Formisano L; Bianco R
    Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188810. PubMed ID: 36202311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma.
    Brisudova A; Skarda J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Jun; 164(2):127-132. PubMed ID: 32284620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifification of a novel LDLR-RET Fusion in Lung Adenocarcinoma.
    Shi G; Luo Y; Yu Z; Wang Y; Zhu B
    Invest New Drugs; 2022 Aug; 40(4):858-860. PubMed ID: 35524867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive molecular pathology in metastatic thyroid cancer: the role of
    Nacchio M; Pisapia P; Pepe F; Russo G; Vigliar E; Porcelli T; Luongo C; Iaccarino A; Pagni F; Salvatore D; Troncone G; Malapelle U; Bellevicine C
    Expert Rev Endocrinol Metab; 2022 Mar; 17(2):167-178. PubMed ID: 35404189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of
    Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
    Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
    Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
    Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
    Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
    Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.